Skip to main content
VRDN
NASDAQ Life Sciences

VRDN-008 Phase 1 Hits 74% IgG Reduction, Every-8-Week Dosing Possible

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$30
Mkt Cap
$3.228B
52W Low
$13.18
52W High
$34.29
52W Position info
128% above low
Off High info
13% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

VRDN has more than doubled off its 52-week low of $13.18 on elevated volume (2.2× avg).

Summary

Viridian's VRDN-008 posted positive Phase 1 data in healthy volunteers: a 15-18 day half-life (up to 6x longer than first-generation Fc fragments) and 74% peak IgG reduction sustained through 8 weeks, supporting every-8-week subcutaneous dosing. No serious adverse events or dose-limiting toxicities were reported, and the drug spared albumin and LDL. Management says it will push VRDN-008 into registrational development starting with myasthenia gravis in mid-2027, pending regulatory feedback, with a two-arm Q4W/Q8W versus placebo design using the Enable enFuse on-body injector. This is the pipeline story that matters beyond Lumvoa, which just delivered its first $24.7 million commercial quarter and left $955.2 million in cash. A best-in-class Q8W FcRn profile would be a major competitive differentiator in autoantibody-mediated disease, though the value hinges on pivotal data that won't start until 2027. A conference call is scheduled for 8:00 a.m. ET today.

At the time of this announcement, VRDN was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $13.18 to $34.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

VRDN - Latest Insights

VRDN
Nov 04, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.75
Real-time Price: $29.00 info
Change: +$1.25 (+5%) info
Market Cap: $3.228B info
VRDN
Nov 04, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $27.09
Real-time Price: $29.00 info
Change: +$1.91 (+7%) info
Market Cap: $3.228B info
VRDN
Aug 06, 2026, 7:31 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.87
Real-time Price: $29.00 info
Change: +$8.13 (+39%) info
Market Cap: $3.228B info
VRDN
Aug 06, 2026, 7:19 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $21.50
Real-time Price: $29.00 info
Change: +$7.50 (+35%) info
Market Cap: $3.228B info
VRDN
Aug 06, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.81
Real-time Price: $29.00 info
Change: +$8.19 (+39%) info
Market Cap: $3.228B info